Showing results (611-620 of 831) with videos related to
Sort By:
Pageof 84
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2022
Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration CohortsPaul M Barr, Alessandra Tedeschi, William G Wierda, et al.Blood|August 28, 2009
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapseFrancis Giles, Norbert Vey, Daniel DeAngelo, et al.Molecular Cancer Research : MCR|March 4, 2015
Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL CellsUri Rozovski, Srdana Grgurevic, Carlos Bueso-Ramos, et al.Cancer|February 6, 2003
Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosisHagop M Kantarjian, Susan O'Brien, Jorge E Cortes, et al.Leukemia Research|December 3, 2019
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trialElias Jabbour, Nicola Gökbuget, Anjali Advani, et al.American Journal of Hematology|April 30, 2014
Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemiaOhad Benjamini, Theresa Liu Dumlao, Hagop Kantarjian, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2005
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemiaWilliam Wierda, Susan O'Brien, Sijin Wen, et al.American Journal of Clinical Pathology|August 19, 2010
High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemiaSergej N Konoplev, Herbert A Fritsche, Susan O'Brien, et al.American Journal of Hematology|July 4, 2014
Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemiaGautam Borthakur, Jorge E Cortes, Elihu E Estey, et al.Blood|June 7, 2003
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemiaHagop Kantarjian, Varsha Gandhi, Jorge Cortes, et al.Pageof 84